The sharply lower production costs in India compared with the highly-regulated West may prompt these second-rung firms to make India an export base, say analysts. In a way, these companies are true counterparts of Indian drug firms, with similar revenue profiles and characteristic focus on generics rather than discovery drugs.
When Israel’s Nasdaq-listed Teva Pharmaceutical Industries, the world’s largest maker of generic drugs with sales above $10 billion, built an active pharmaceutical ingredient (API) plant in Malanpur, Madhya Pradesh, in 2008, few thought it would herald a trend. Many others seem to have followed in Teva’s footsteps. Illinois-based $4-billion Hospira, carved out of Abbott Laboratories roughly a decade ago, is setting up a generic injectables unit at Visakhapatnam in Andhra Pradesh for $375-450 million.
Hospira spokesperson Dan Rosenberg told FE the company would start producing a range of specialty injectables by end-2014.
The plant is coming up on the land for which Hospira got lease rights as it bought Chennai-based Orchid Chemicals and Pharmaceuticals’ generic injectables business in 2010. Rosenberg said: “Hospira recognised India’s strong manufacturing capabilities and decided to use the land for our manufacturing expansion. India has strong manufacturing capabilities and an experienced and dedicated workforce, and we’re excited about our Vizag plant.”
Of course, many products the foreign generic companies are planning to manufacture here have domestic alternatives, but these facilities may also bring in new varieties of specialty generics for Indian consumers.
Teva’s 72.6-acre facility in Madhya Pradesh was set up in 2008 and is one of its two Indian API plants, the other one being a brownfield project. The drugmaker with $4.92-billion revenues for the quarter ended June 30, is now building a plant at Sanand in Gujarat. The plant, a joint venture between Teva and Procter & Gamble, will manufacture over-the-counter products for domestic and Asia-Pacific markets.
Teva spokesperson Yonatan Beker said the company had bought the land for $13.3 million and that construction would take about two years. “Our comprehensive analysis showed that the Sanand site best aligned with all of our site selection criteria, including the availability of qualified workers, physical infrastructure and the favourable business environment,” Yonatan Beker said.
Top-notch innovators like GlaxoSmithKline Sanofi-Aventis and Pfizer – and to an extent, Novartis and Roche as well – have been in India for decades. They are convinced about India’s potential as an R&D base and say that if the country’s intellectual property regime were more liberal, their investments could increase.
Bristol-Myers Squibb and Boehringer Ingelheim had set up wholly-owned Indian subsidiaries before 2005, expecting benefits once product patents were in place; however, these companies haven’t scaled up significantly.
India is among the top-five pharma-emerging economies in the world with a spending power of $14.3 billion in 2011, which is expected to grow at a compounded annual growth rate of 14-17% during 2012-2016.
“If foreign drugmakers are going to serve emerging markets like India, Brazil or China and have high-priced plants elsewhere, its not going to work. So, you have to be near those locations or at those locations which are generating that demand,” PricewaterhouseCoopers executive director Sujay Shetty said, adding India has a long history of exporting to US markets.
India’s 170-180 US FDA-compliant manufacturers and the consequent high quality of drugs has made it a hot destination for foreign drugmakers, says Shetty. Cheaper capital equipment and lower engineering costs which have reduced overall manufacturing costs by at least 40% too add to the allure.
The biggest takeovers of Indian drug makers in recent years include that of Ranbaxy Laboratories Ltd by Daiichi Sankyo, Matrix Labs by Mylan and Piramal Healthcare by Abbott.
Highlighting the regulatory concerns over brownfield pharma FDI, a parliamentary panel recently said these investments have not added fresh capacity in terms of production. With the trend of foreign generic drug-makers setting up facilities in India, these fears are unfounded, analysts feel.